Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD52 expression in hairy cell leukemia.

Michael M Quigley1, Kelly J Bethel, Robert W Sharpe

  • 1Division of Hematopathology, Scripps Clinic Laboratories, Scripps Clinic, La Jolla, California 92037, USA. mmquigley@nmcsds.med.navy.mil

American Journal of Hematology
|November 25, 2003
PubMed
Summary

Hairy cell leukemia (HCL) is a rare B-cell cancer. This study found that HCL cells express CD52, supporting the use of alemtuzumab (anti-CD52) for treating refractory HCL cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Dose Vemurafenib Plus Rituximab in Front-Line and Relapsed or Refractory Hairy Cell Leukemia: The Scripps Regimen.

Blood advances·2026
Same author

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab.

British journal of haematology·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Expert consensus opinion on the management of hairy cell leukemia in elderly patients.

Leukemia & lymphoma·2025
Same author

IgG3κ Monoclonal Membranous Nephropathy Associated With Acquired Lecithin Cholesterol Acyltransferase Deficiency.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2025
Same author

Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.

Leukemia & lymphoma·2025

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Hairy cell leukemia (HCL) is a rare chronic B-cell lymphoproliferative disorder.
  • Refractory HCL cases have limited treatment alternatives.
  • Monoclonal antibody therapy, such as alemtuzumab (anti-CD52), shows promise for B-cell malignancies.

Purpose of the Study:

  • To investigate CD52 antigen expression on malignant cells in HCL.
  • To determine the rationale for using alemtuzumab in refractory HCL.

Main Methods:

  • Flow cytometry was used to analyze CD52 expression.
  • Nine cases of HCL and one HCL variant were examined.

Main Results:

  • All examined HCL cases showed high expression of CD52 antigen (92-100%) on malignant cells.

Related Experiment Videos

  • CD52 expression was consistently demonstrated on HCL cells.

    • Conclusions:

    • The consistent CD52 antigen expression on HCL cells provides a strong rationale for alemtuzumab therapy.
    • Alemtuzumab is a potential treatment option for patients with refractory HCL.